TR-1: Notification of Major Interest in Shares

17th Sep 2010 07:00

For filings with the FSA include the annex For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are Sinclair Pharma plc

attached:ii

2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X

An acquisition or disposal of qualifying financial instruments which may result

in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments An event changing the breakdown of voting rights

Other (please specify): Abingworth LLP

3. Full name of person(s) subject to the

notification obligation:iii Abingworth Bioventures V LP Abingworth Bioequities Master Fund Limited

4. Full name of shareholder(s)

(if different from 3.):iv

5. Date of the transaction and date on 10 December 2009 which the threshold is crossed or

reached: v

6. Date on which issuer notified: 16 September 2010 7. Threshold(s) that is/are crossed or Above 3% - Abingworth LLP

reached: vi, vii

8. Notified details: Abingworth LLP A: Voting rights attached to shares viii, ix Class/type of Situation previous Resulting situation after the triggering transaction shares to the triggering transaction if possible Number Number Number Number of voting % of voting rights x using of of of shares rights the ISIN CODE Shares Voting Rights Direct Direct xi Indirect Direct Indirect xii Sinclair Pharma plc GB0033856740 0 0 0 0 5,353,650 3.3% 1p Ords

B: Qualifying Financial Instruments Resulting situation after the triggering transaction Type of financial Expiration Exercise/ Number of voting % of voting instrument date xiii Conversion Period xiv rights that may be rights acquired if the instrument is exercised/ converted. C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial Exercise Expiration Exercise/ Number of voting rights % of voting rights instrument price date xvii Conversion instrument refers to xix, xx period xviii Nominal Delta Total (A+B+C) Number of voting rights Percentage of voting rights 5,353,650 3.3%

9. Chain of controlled undertakings through which the voting rights and/or the

financial instruments are effectively held, if applicable: xxi Abingworth Bioventures V LP (which holds 3,569,100 shares in the company

(2.2%)) and Abingworth Bioequities Master Fund Limited (which holds 1,784,550

shares in the company (1.1%)) are both managed by Abingworth LLP.

Proxy Voting:

10. Name of the proxy holder: 11. Number of voting rights proxy holder will cease

to hold:

12. Date on which proxy holder will cease to hold

voting rights: 13. Additional information: 14. Contact name: John Heard 15. Contact telephone number: 0207 534 1508

vendor

---

Related Shares:

Sinclair Pharma